New hope for hard-to-treat colon cancer: combo attack with immunotherapy and radiation

NCT ID NCT07502014

Not yet recruiting Disease control Sponsor: Huazhong University of Science and Technology Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 study tests whether adding an immunotherapy drug (iparomlimab and tuvonralimab) and targeted radiation to a standard targeted therapy (fruquintinib) can help people with metastatic colorectal cancer that has spread to a few spots. The trial will enroll 60 adults who have already tried at least two prior treatments. Half will get the new combo, half will get fruquintinib alone, and researchers will compare how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: iparomlimab and tuvonralimab (QL1706) plus fruquintinib plus radiotherapy
What this could lead to: If successful, this could offer a new treatment option for people with advanced colorectal cancer that has stopped responding to earlier therapies.
What could go wrong: This is a small, early-phase trial with only 60 participants, so results may not apply to everyone. The combination also carries risks of immune-related side effects and radiation toxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MCRC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MCRC METASTATIC COLORECTAL CANCER (CRC)

More trials for these conditions

Other studies related to the condition(s) this trial covers.